We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Mitoses Counted with Digital Pathology in Breast Phyllodes Tumors

By LabMedica International staff writers
Posted on 26 Nov 2020
Print article
Image: IntelliSite Ultra-Fast Digital pathology slide scanner is designed to accommodate current histopathology needs for routine use in high volume labs and integrated pathology networks (Photo courtesy of Philips Digital Pathology Solutions).
Image: IntelliSite Ultra-Fast Digital pathology slide scanner is designed to accommodate current histopathology needs for routine use in high volume labs and integrated pathology networks (Photo courtesy of Philips Digital Pathology Solutions).
Phyllodes tumors (PTs) are a fibroepithelial tumor composed of an epithelial and a cellular stromal component. They may be considered benign, borderline, or malignant depending on histologic features including stromal cellularity, infiltration at the tumor's edge, and mitotic activity.

Digital pathology (DP) is becoming more widely available and has been harnessed to enhance diagnosis and access to subspecialty opinion, promote education, and may also be deployed for remote reporting. DP has enabled the development of artificial intelligence (AI) in pathology, through image analysis and machine learning, including working toward open source access.

Pathologists at the Singapore General Hospital (Singapore) and their colleagues chose representative slides from 93 cases of PTs diagnosed between 2014 and 2015. The mean age ± SD of the cohort was 42.5 ± 12.7 years. Of these, 60 were benign, 31 borderline, and two malignant, which were graded based on the World Health Organization guidelines. Specifically, stromal hypercellularity and stromal atypia were categorized into mild, moderate, and marked, according to the consensus review.

The slides were scanned with the IntelliSite Ultra-Fast Scanner (Philips Digital Pathology Solutions, Eindhoven, the Netherlands) and viewed with the Philips’ Image Management System viewer. Mitotic counting was conducted on the whole slide image, before choosing 10 high powered fields (HPFs) and demarcating the tumor area in DP. Values of mitoses/mm2 were used to compare results between 10 HPFs and the whole slide. Correlations with clinicopathological parameters were conducted.

The scientists reported that in terms of atypia, 65 (70.0%) PT cases displayed mild atypia, followed by 27 (29.0%) moderate atypia and one (1%) marked atypia. For stromal cellularity, 50 (53.8%) tumors displayed moderate hypercellularity, followed by 31 (33.3%) mild hypercellularity and 12 (12.9%) marked hypercellularity. The mean size of the tumors was 4.6 ± 3.3 cm3 (mean ± SD cm3). Both whole slide counting of mitoses and 10 HPFs had similar statistically significant correlation coefficients with grade, stromal atypia, and stromal hypercellularity. Neither whole slide mitotic counts nor mitoses per 10 HPFs showed statistically significant correlations with patient age and tumor size.

The authors concluded that an accurate set of 10 HPFs that yielded a maximal mitotic count can be chosen after evaluating the whole slide. DP makes counting mitoses over a larger area subjectively easier, with the possibility of AI being used as facilitator and enabler. This could influence how to approach training, testing, and validation of future AI algorithms for mitotic counting. The study was published in the November. 2020 issue of the journal Archives of Pathology and Laboratory Medicine.

Related Links:
Singapore General Hospital
Philips Digital Pathology Solutions



Print article

Channels

Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more

Industry

view channel
Illustration

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.